IPHYF News and Press, Innate Pharma - Class A From 05/15/25

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that an abstract regarding IPH6501, its ANKET ® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgk...

2025-05-13 13:51:34 ET Innate Pharma S.A. (IPHA) Q1 2025 Earnings Conference Call May 13, 2025 8:00 am ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer Yannis Morel - Chief Operating Officer Soni...

2025-05-13 13:47:49 ET More on Innate Pharma S.A. Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript Innate Pharma S.A. 2024 Q4 - Results - Earnings Call Presentation Innate Pharma: Moving Into The Padcev Space Historical earnings data for Innate Phar...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET ® program in autoimmune indications First patient dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumo...

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2024 Universal Registration Document ( Document d’enregistrement universel ) for the year ending December 31, ...

IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated superior preclinical anti-tumor activity compared to enfortumab vedotin (EV) in urothelial carcinoma models with low or hetero...

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...